Abstract
The transcriptomic characteristics and subtypes of MPA/DMBA-induced mouse mammary 23 tumors were determined using gene expression microarrays. Somatic mutations and copy 24 number aberrations in MPA/DMBA-induced tumors were identified from whole exome 25 sequencing data. A publicly available dataset was queried to explore the genomic 26 characteristics of human claudin-low breast cancer and to validate findings in the murine 27
tumors. 28
Half of MPA/DMBA-induced tumors showed a claudin-low-like subtype. All tumors carried 29 mutations in known driver genes. While the specific genes carrying mutations varied between 30 tumors, there was a consistent mutational signature with an overweight of T>A transversions 31 in TG dinucleotides. Most tumors carried copy number aberrations with a potential oncogenic 32
Introduction

63
The claudin-low subtype of breast cancer (BC) is a distinct disease entity associated with a 64 counterparts. In parallel, we analyzed the previously unexplored genomic features of human 89 claudin-low breast cancer. Our findings highlighted several features of claudin-low breast 90 cancer with potential therapeutic implications, including a low tumor mutational burden, high 91 expression of the immune checkpoint gene CD274 (encoding PD-L1) and high expression of 92 PTGS2 (encoding cyclooxygenase-2). 93 94 95
Results
96
Gene expression subtyping reveals two distinct tumor clusters 97
We determined the murine transcriptomic subtypes of 17 MPA/DMBA-induced mammary 98 tumors from 13 mice (S1 File) by performing a hierarchical clustering of gene expression data 99 using the mouse intrinsic gene list [11] . This revealed nine murine subtypes in the cohort (Fig  100   1 , Table 1 , S2 File). The tumors separated into two distinct clusters. One cluster consisted of 101 claudin-low Ex and squamous-like Ex tumors, both of which have been shown to resemble the 102 human claudin-low subtype [11] ; this is therefore referred to as the claudin-low-like cluster. 103
The other cluster contained tumors from seven different subtypes and is referred to as the 104 mixed cluster. In four instances, two tumors from different mammary glands were harvested 105 from the same mouse. These were classified as different subtypes in all cases and are 106 presumed to be distinct primary tumors. All normal mammary gland samples were classified 107 as normal-like Ex , and clustered separately from the tumors. 108 To determine the genetic characteristics of the tumors, we performed exome sequencing to a 121 mean depth of 58, with 84% of bases being sequenced to a coverage of 20x or higher. We 122 identified a mean of 589 mutations per tumor (range: 288 to 1795), corresponding to a mean 123 mutation rate of 11.9 mutations per megabase (range: 5.8 to 36.2) (Fig 2B) . This is 124 substantially higher than the average 1.3 mutations per megabase found in human breast 125 cancer [19] . There was no significant difference in mutational burden between the tumors in 126 the claudin-low-like and the mixed cluster, and the only subtype specific trend was a 127 particularly high mutational burden in the two squamous-like Ex tumors (Fig 2B) . 128
All tumors carried mutations in driver genes defined by the COSMIC cancer gene census list 129
[20], with a mean of 13.8 driver genes carrying mutations per tumor (range: 4 to 29) (Fig 2A) 
There were marked disparities between the gene mutational profiles of human breast cancer 151
[22] and MPA/DMBA-induced tumors (Fig 2C, S5 File) . The two most frequently mutated 152 genes in breast cancer are PIK3CA and TP53. While TP53 showed comparable mutation rates 153 between human breast cancer and MPA/DMBA-induced tumors (34% and 28%, 154 respectively), PIK3CA mutation does not appear to be a common event in MPA/DMBA We observed two sets of tumors carrying remarkably similar CNA profiles (Fig 3B) . None of 195 the tumors in these two sets displayed the same murine subtype as any other tumor within the 196 same set. 197
The human claudin-low breast cancer genome is characterized by a low 198 mutational burden, frequent TP53 mutations and a low rate of CNA 199 Little has been published specifically describing the genomic characteristics of human 200 claudin-low breast cancer. We therefore analyzed the 218 claudin-low tumors found in the 201 METABRIC dataset, for which DNA sequence data from 173 genes and whole genome copy 202 number data is available [6, 7] . There was a high degree of overlap between the genes most frequently mutated in claudin-low 210 breast cancers and the genes most frequently mutated in all other breast cancers ( Fig 4B) . 211
Most of these genes carried mutations at similar rates between claudin-low and non-claudin-212 low tumors, albeit with a tendency towards a slightly lower rate in claudin-low tumors. There 213 were however two notable differences in mutational frequency: a significantly higher rate of 214 We identified a significantly elevated expression of two potentially actionable genes related to 249 immunosuppression in the claudin-low-like tumors: the immune checkpoint encoding gene 250
Cd274 and the cyclooxygenase encoding gene Ptgs2 (Fig 5B) . These features were also 251 characteristic of human claudin-low tumors in the METABRIC cohort [6, 7] , which showed 252 significantly higher expression levels of both PTGS2 and CD274 compared to non-claudin-253 low breast tumors (p < 0.001 for both, two-tailed Wilcoxon rank-sum test), and compared 254 specifically to basal-like tumors (p = 0.004 and p < 0.001, respectively) ( Fig 5C) The tumor is initiated when one or more driver mutations occur, for example Trp53 or Ras-288 mutation, with the tumor phenotype, however, determined by non-genomic factors. The 289 biochemical mechanism of DMBA-induced mutagenesis has been described [14,15], whereas 290 no causal mechanism for DMBA-induced copy number aberration is known; it is therefore 291 likely that CNAs arise after tumor initiation. 
Material and Methods
335
Ethics statement 336
The Norwegian Food Safety Authority approved all experiments in advance of their 337 implementation (FOTS ID #4385). All mice were bred and maintained within a specific 338 pathogen free (SPF) barrier facility according to local and national regulations, with food and 339 water ad libitum. For invasive procedures, animals were anaesthetized with sevoflurane gas. 
Histopathology and immunohistochemistry 361
Mouse tissue was fixed overnight in 4% PFA, routinely processed and paraffin embedded. 362
Formalin-fixed paraffin-embedded tissue was sectioned and stained with hematoxylin and 363 eosin (HE). HE-stained tissue was classified by a certified veterinary pathologist. 364
Immunohistochemical staining was performed as previously described [ manufacturer's protocol. DNA from two samples (S159_14_11 and S176_14_11) was isolated 372 using CTAB Extraction Solution (Biosesang cat.# C2007) per manufacturer's protocol. DNA 373 integrity was assessed by electrophoresis and concentration was determined using the 374 Nanodrop ND-1000 spectrophotometer (Thermo Scientific cat.# ND-1000) and Qubit 375 fluorometer (Thermo Scientific cat.# Q33226). Total RNA and DNA isolation for gene 376 expression microarrays was carried out using the QIAcube system (Qiagen cat.# 9001292) 377 with the AllPrep DNA/RNA Universal Kit (Qiagen cat.# 80224) according to the protocol 378 provided by the supplier, with 30mg tissue as input. The tissue was manually minced with a 379 scalpel on ice followed by lysis and homogenization using TissueLyzer LT (Qiagen cat.# 380 85600) and Qiashredder (Qiagen cat.# 79654), respectively. Nucleic acid concentrations were 381 measured by NanoDrop ND-1000 spectrophotometer and RNA integrity was analyzed using 
Gene expression analyses 394
Gene expression data was analyzed using Qlucore Omics Explorer 3.2 (Qlucore AB) and R 395 
Copy number aberration analyses 449
Copy number aberrations were identified from exome sequence data using EXCAVATOR2 450
[64] using the mm10 reference genome. CNA calling was performed using standard settings, 451 and a window size of 20000 base pairs. To identify potential driver CNAs, we filtered for 452
Plot generation 457
Plots were created using R version 3.3.2 [46]. Heatmaps were created using 458
ComplexHeatmap [67] . Mutational spectra histograms were created using the deconstructSigs 459 package [63] . All other plots were generated using the ggplot2 package [68] . 
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